EU approves Aybintio for carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube and peritoneal cancer and cervical cancer.- Samsung Bioepis

eFFECTOR Therapeutics, Inc. a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced topline results from the primary analysis of the randomized Phase II KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ?50%.

Merck Inc., known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults.